IMDX
Insight Molecular Diagnostics Inc.Company Information
- Company Name
- Insight Molecular Diagnostics Inc.
- CIK
- CIK0001642380
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IMDX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- IMDX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-27
- Last sale
- —
- Shares purchased (TTM)
- 813,352
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 18,282,036
- Shares outstanding
- 36,750,000
- Ownership
- 49.75%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -13.42%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 18 | 28 | 12 | 19 | 24 | 31 | 9 | 3 | 9 | 6 | 9 | 14 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 0 | 1 | ||||||
| Equity Securities Fv Ni | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 21 | 31 | 15 | 21 | 27 | 36 | 12 | 5 | 10 | 7 | 11 | 17 | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | - | - | - | - | ||||||
| Deferred Finance Costs Net | - | - | 0 | - | - | - | 0 | 0 | - | - | - | - | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Finance Lease Right Of Use Asset | - | - | - | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 0 | 15 | 15 | 15 | 15 | 57 | 57 | 57 | 57 | 57 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | ||||||
| Assets | 29 | 40 | 26 | 44 | 51 | 60 | 35 | 70 | 75 | 71 | 75 | 82 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 2 | 3 | 3 | - | - | - | 1 | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 2 | 3 | 2 | 2 | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | ||||||
| Accrued Royalties Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | ||||||
| Liabilities Current | 10 | 12 | 12 | 8 | 7 | 10 | 7 | 9 | 7 | 8 | 7 | 8 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Current | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | - | - | 2 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Noncurrent | 40 | 38 | 43 | 44 | 41 | 38 | 38 | 49 | 42 | 43 | 40 | 29 | ||||||
| Liabilities | 51 | 51 | 57 | 53 | 49 | 50 | 47 | 61 | 52 | 54 | 49 | 39 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | 5 | 5 | 5 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 395 | 394 | 369 | 369 | 368 | 367 | 338 | 327 | 326 | 311 | 310 | 310 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -21 | -11 | -31 | -9 | 1 | 10 | -12 | 10 | 23 | 12 | 20 | 36 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -416 | -405 | -401 | -378 | -367 | -357 | -351 | -317 | -304 | -299 | -290 | -262 | ||||||
| Liabilities And Stockholders Equity | 29 | 40 | 26 | 44 | 51 | 60 | 35 | 70 | 75 | 71 | 75 | 82 | ||||||
| Allowance For Doubtful Accounts Receivable | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Preferred Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 230 | 230 | 230 | 230 | 230 | 230 | 230 | 230 | 230 | 230 | 230 | 230 | ||||||
| Common Stock Shares Issued | 33 | 32 | 29 | 29 | 29 | 29 | 17 | 13 | 13 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 33 | 32 | 29 | 29 | 29 | 29 | 17 | 13 | 13 | 8 | 8 | 8 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInsight Molecular Diagnostics Inc. (IMDX) — SEC Financial Statements & Analysis
Insight Molecular Diagnostics Inc. (IMDX) is a in vitro & in vivo diagnostic substances company, incorporated in CA. Insight Molecular Diagnostics Inc. trades on Nasdaq as: IMDX. Insight Molecular Diagnostics Inc. (IMDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Insight Molecular Diagnostics Inc. carries a market cap of $216.83M, a P/E ratio of -4.39x, a P/B ratio of -10.18x, a P/S ratio of 129.84x, an enterprise value of $199.07M, and an EV/EBITDA multiple of -4.16x. On profitability, it posts a gross margin of 48.32%, an operating margin of -3011.86%, a net margin of -2955.63%, a Return on Equity (ROE) of 488.68%, a Return on Assets (ROA) of -123.46%, and a Return on Invested Capital (ROIC) of -303.24%. Per share, it reports EPS of $-1.34, diluted EPS of $-1.34, free cash flow per share of $-0.84, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -60.77% year-over-year, net income growth of -22.42% year-over-year, and EPS growth of -32.40% year-over-year. On the balance sheet, it maintains a current ratio of 2.00x, a quick ratio of 1.82x, working capital of $10.26M, a debt-to-equity ratio of -2.38x, a debt ratio of 1.72, an interest coverage ratio of -513.24x, free cash flow of $-31.00M (TTM), and net debt of $-17.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $216.83M
- P/E TTM
- -4.39x
- EPS TTM
- $-1.34
- P/B TTM
- -10.18x
- ROE TTM
- 488.68%
- ROA TTM
- -123.46%
- Debt To Equity
- -2.38x
- Free Cash Flow TTM
- $-31.00M
- Net Revenue TTM Growth 1Y
- -60.77%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Insight Molecular Diagnostics Inc. in?
Insight Molecular Diagnostics Inc. (IMDX) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does IMDX trade on?
Insight Molecular Diagnostics Inc. (IMDX) trades on the Nasdaq.
Where is Insight Molecular Diagnostics Inc. incorporated?
Insight Molecular Diagnostics Inc. is incorporated in CA.
When was Insight Molecular Diagnostics Inc. (IMDX)'s most recent SEC filing?
Insight Molecular Diagnostics Inc. (IMDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is IMDX's market cap?
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $216.83M as of 2026-06-30.
What is IMDX's EPS (earnings per share)?
Insight Molecular Diagnostics Inc. (IMDX)'s trailing twelve month EPS is $-1.34 as of 2026-06-30.
What is IMDX's ROE (return on equity)?
Insight Molecular Diagnostics Inc. (IMDX)'s trailing twelve month Return on Equity (ROE) is 488.68% as of 2026-06-30.
What is IMDX's ROA (return on assets)?
Insight Molecular Diagnostics Inc. (IMDX)'s trailing twelve month Return on Assets (ROA) is -123.46% as of 2026-06-30.
What is IMDX's ROIC (return on invested capital)?
Insight Molecular Diagnostics Inc. (IMDX)'s trailing twelve month Return on Invested Capital (ROIC) is -303.24% as of 2024-09-30.
What is IMDX's EV/EBITDA?
Insight Molecular Diagnostics Inc. (IMDX)'s trailing twelve month EV/EBITDA is -4.16x as of 2026-06-30.